Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"
Jump to navigation
Jump to search
Line 4: | Line 4: | ||
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue = | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref> | *~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue = | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref> | ||
*May represent ''or'' overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}} | *May represent ''or'' overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}} | ||
*The main differential diagnosis is ''metastatic adenocarcinoma''. | |||
==IHC== | ==IHC== | ||
Features:<ref name=pmid28555282/> | Features:<ref name=pmid28555282/> | ||
*CK7 +ve. | *CK7 +ve. | ||
*TTF-1 -ve. | *[[TTF-1]] -ve. | ||
*HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | *HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | ||
*SMARCA4 -ve. | *SMARCA4 -ve. |
Revision as of 21:00, 30 October 2023
SMARCA4-deficient non-small cell carcinoma of the lung is an emerging subtype of lung cancer.[1]
General
- ~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.[2]
- May represent or overlap with what is known as hepatoid adenocarcinoma of the lung.[citation needed]
- The main differential diagnosis is metastatic adenocarcinoma.
IHC
Features:[1]
Note:
- Hepatoid adenocarcinoma of lung shows cytoplasmic TTF-1 staining.[3]
Sign out
The tumour stains as follows: POSITIVE: CK7 (diffuse, strong), HepPar-1 (strong, diffuse). NEGATIVE: TTF-1, napsin A, p63, CK5/6. The staining pattern for this tumour is not typical for lung adenocarcinoma; please correlate with the clinical findings. HepPar-1 POSITIVITY with CK7 POSITIVITY and TTF-1 NEGATIVITY may be seen in SMARCA4-deficient adenocarcinoma of the lung.[1] 1. Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
See also
- Lung adenocarcinoma.
- SMARCB1 (INI-1).
References
- ↑ 1.0 1.1 1.2 Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
- ↑ Herpel, E.; Rieker, RJ.; Dienemann, H.; Muley, T.; Meister, M.; Hartmann, A.; Warth, A.; Agaimy, A. (Feb 2017). "SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.". Ann Diagn Pathol 26: 47-51. doi:10.1016/j.anndiagpath.2016.10.006. PMID 28038711.
- ↑ Haninger, DM.; Kloecker, GH.; Bousamra Ii, M.; Nowacki, MR.; Slone, SP. (Apr 2014). "Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature.". Mod Pathol 27 (4): 535-42. doi:10.1038/modpathol.2013.170. PMID 24030743.